Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$48.44 USD

48.44
11,207,997

+0.63 (1.32%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $48.50 +0.06 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Prothena's (PRTA) Q4 loss was narrower than expected, while revenues missed expectations.

Zacks Equity Research

Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%

by Zacks Equity Research

AstraZeneca (AZN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Equity Research

Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

by Zacks Equity Research

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

Zacks Equity Research

Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up

by Zacks Equity Research

Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.

Zacks Equity Research

5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

by Zacks Equity Research

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

Zacks Equity Research

BMY vs. AZN: Which Stock Is the Better Value Option?

by Zacks Equity Research

BMY vs. AZN: Which Stock Is the Better Value Option?

Zacks Equity Research

AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.

Zacks Equity Research

Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4

by Zacks Equity Research

Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.

Zacks Equity Research

J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod

by Zacks Equity Research

J&J (JNJ) gets FDA advisory committee's positive recommendation for its investigational nasal spray, Spravato (esketamine) for treatment-resistant depression in adults.

Swarup Gupta headshot

5 Tiny Biotech Stocks With Superb Growth Potential

by Swarup Gupta

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Zacks Equity Research

Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100

by Zacks Equity Research

Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.

Zacks Equity Research

Bristol-Myers' Sprycel Gets European Nod for Label Expansion

by Zacks Equity Research

Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.

Zacks Equity Research

Seattle Genetics' Adcetris Gets EC Nod for Label Expansion

by Zacks Equity Research

Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

Zacks Equity Research

Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review

by Zacks Equity Research

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.

Zacks Equity Research

AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

by Zacks Equity Research

AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Bristol-Myers, ConocoPhillips, Qualcomm, General Motors and Marathon

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Bristol-Myers, ConocoPhillips, Qualcomm, General Motors and Marathon

Zacks Equity Research

This is Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

Zacks Equity Research

3 Reasons Growth Investors Will Love Bristol-Myers (BMY)

by Zacks Equity Research

Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.

Mark Vickery headshot

Top Analyst Reports for Bristol-Myers, ConocoPhillips & Qualcomm

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY), ConocoPhillips (COP) and Qualcomm (QCOM).

Zacks Equity Research

Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.

Zacks Equity Research

Exelixis (EXEL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.

Zacks Equity Research

Zacks.com featured highlights include: Starbucks, Bristol-Myers, Portland General Electric, Foot Locker and J.B. Hunt

by Zacks Equity Research

Zacks.com featured highlights include: Starbucks, Bristol-Myers, Portland General Electric, Foot Locker and J.B. Hunt

Swarup Gupta headshot

Winners & Losers from Trump's State of the Union Address

by Swarup Gupta

While pharma majors could face greater scrutiny on drug pricing, defense, infrastructure and energy are likely to emerge as big winners.

Zacks Equity Research

5 Stocks With Strong Sales Growth Worth Buying Right Now

by Zacks Equity Research

Strong sales growth is one of the most important characteristics of potential winners in the stock market.

Zacks Equity Research

Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.